LUM001 (Maralixibat)
Sponsors
Mirum Pharmaceuticals, Inc.
Conditions
Alagille SyndromeProgressive Familial Intrahepatic Cholestasis (PFIC)
Phase 2
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
CompletedNCT02047318
Start: 2013-12-20End: 2020-06-17Updated: 2021-11-19
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
CompletedNCT02057718
Start: 2014-03-01End: 2020-05-08Updated: 2023-10-23
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
CompletedNCT02117713
Start: 2015-03-16End: 2020-06-01Updated: 2021-07-01
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
CompletedNCT02160782
Start: 2014-10-28End: 2020-05-28Updated: 2021-07-14